Seeking Alpha

Aeterna Zentaris (AEZS) is up 8.5% premarket after announcing favorable results for a Phase 3...

Aeterna Zentaris (AEZS) is up 8.5% premarket after announcing favorable results for a Phase 3 study related to its AEZS-130 drug for treating adult growth hormone deficiency. The company now plans to consult with the FDA regarding the submission of a new drug application (NDA).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|